In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
1889 News Items found
MSK patient Zachary Levine
Sunrise Day Camp: Where Kids with Cancer — and Their Siblings — Can Be Kids for the Summer

Discover how Sunrise Association Day Camps are transforming summer for children affected by cancer.
CT scans of brains
Finding
Research Advances the Genetic Understanding of Pineoblastoma, a Rare Brain Cancer

The findings will lead to more accurate diagnoses and, potentially, to better treatments.
MSK surgeon José Guillem and patient Elliot Katz
In the Clinic
A Family Discovers an Unexpected Cancer Risk in Their Genes

Two brothers discuss their surprise at being diagnosed with Lynch syndrome.
MSK computational biologist Barry Taylor
Finding
Double Jeopardy: Gene-Sequencing Test Uncovers New Clues about a Defect Seen in Many Tumors

MSK researchers have found that a genetic state in tumors called whole-genome doubling is connected with worse outcomes for people with cancer.
MSK physician-scientist Omar Abdel-Wahab
In the Lab
Splicing May Be an Effective Target in the Fight against Cancer

New drugs are being developed that target part of the process to make proteins.
MSK sarcoma doctor William Tap with a patient
In the Clinic
Six Things to Know about Soft Tissue Sarcoma Recurrence

If you've been treated for soft tissue sarcoma, a recurrence may be a big concern for you. Here's what MSK's sarcoma experts think you should know about the disease coming back.
MSK Researchers Have Identified a Doubling Chromosome That Can Help Predict Outcomes in People with Cancer

Experts at Memorial Sloan Kettering Cancer Center (MSK) have identified genome doubling in cancer and have correlated it to a worse prognosis across cancer types. Using MSK-IMPACT™ to analyze matched tumor and normal DNA, MSK researchers were able to identify an abnormality in tumors known as genome doubling. This doubling occurs in 28 percent of all cancers and could have significant implications for treatment options in the future.
Side-by-side images of brain MRIs.
Feature
New Imaging Technique Provides Snapshot of Brain Tumor Activity

A new imaging approach could shorten the time needed to determine whether a brain tumor treatment is working.
NK cells attacking
Feature
Meet the Unsung Immune Cell that Could Change Immunotherapy

A lesser-known immune cell is suddenly getting more attention in the field of cancer immunology.
Findings from People with Acute Myeloid Leukemia Point to a New Understanding of Drug Resistance

Drug resistance is a formidable challenge in cancer treatment. A drug called enasidenib (Idhifa®) was approved by the US Food and Drug Administration last year for the treatment of people with a form of acute myeloid leukemia (AML) that’s driven by a mutation in the gene IDH2. About 15 percent of people with AML have this mutation. Research led by Memorial Sloan Kettering Cancer Center (MSK) reports that people who take enasidenib can develop resistance to it — in a way never seen before. Enasidenib works differently than most cancer drugs. Rather than killing leukemia cells, it turns them into normal blood cells. The discovery of this unique resistence may lead to more-precise treatments for people with AML in the future.